Veracyte Expands Into Urologic Cancer Testing By Acquiring Decipher For $600M
With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.
You may also be interested in...
The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
The 9,000-patient clinical study will identify genomic and other differences in lung cancer development and progression among patients with lung nodules detected by computed tomography.